TNFRSF4 and chronic myelogenous leukemia, BCR-ABL1 positive: To demonstrate the in vivo relevance of our findings, BL/6 CML mice were treated with either control IgG or an agonistic Tnfrsf4 antibody starting at day 12 day after CML induction, and disease development was monitored.